Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation

British Journal of Haematology

Volumn 160, Issue 6, 2013, Pages 798-805

  Aung, Fleur M ^a   Lichtiger, Benjamin ^a   Bassett, Roland ^a   Liu, Ping ^a   Alousi, Amin ^a   Bashier, Qaiser ^a   Ciurea, Stefan O ^a   de Lima, Marcos J ^a   Hosing, Chitra ^a   Kebriaei, Partow ^a   Nieto, Yago ^a   Oran, Betul ^a   Parmar, Simrit ^a   Qazilbash, Muzaffar ^a   Shah, Nina ^a   Khouri, Issa ^a   Champlin, Richard E ^a   Popat, Uday ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Blood groups; Major ABO incompatibility; Pure red cell aplasia

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; IRON OVERLOAD; MALE; MICROCHIMERISM; NEUTROPHIL; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REPEATED DRUG DOSE; RISK FACTOR; T LYMPHOCYTE; THROMBOCYTE;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RED-CELL APLASIA, PURE; RETROSPECTIVE STUDIES; TEXAS; TRANSPLANTATION IMMUNOLOGY; YOUNG ADULT;

EID: 84874731503     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12210     Document Type: Article

References (24)

1. Andersson, B.S., de Lima, M., Thall, P.F., Wang, X., Couriel, D., Korbling, M., Roberson, S., Giralt, S., Pierre, B., Russell, J.A., Shpall, E.J., Jones, R.B. & Champlin, R.E. (2008) Once daily i.v Busulfan and Fludarabine (i.v. Bu-Flu) compares favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biology of Blood and Marrow Transplantation, 14, 672-684.
2. Bacigalupo, A. (2004) Third EBMT/AMGEN workshop on reduced-intensity conditioning allogeneic hematopoietic stem cell transplants (RIC-HSCT) and panel consensus. Bone Marrow Transplantation, 33, 691-696.
3. Barge, A.J., Johnson, G., Witherspoon, R. & Torok-Storb, B. (1989) Antibody medicated marrow failure after allogeneic bone marrow transplantation. Blood, 74, 1477-1480.
4. Bensinger, W.I., Buckiner, C.D., Thomas, E.D. & Clift, R.A. (1982) ABO-incompatible marrow transplants. Transplantation, 33, 427-429.
5. Bolan, C.D., Leitman, S.F., Griffith, L.M., Wesley, R.A., Proctor, J.L., Stroncek, D.F., John Barrett, A.J. & Childs, R.W. (2001) Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood, 98, 1687-1694.
6. Busca, A., Falda, M., Manzini, P., D'Antico, S., Valfre, A'., Locatelli, F., Calabrese, R., Chiappella, A., D'Ardia, S., Longo, F. & Piga, A. (2010) Iron Overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biology of Blood and Marrow Transplantation, 16, 115-122.
7. Couriel, D.R., Saliba, R.M., Giralt, S., Khouri, I., Andersson, B., de Lima, M., Hosing, C., Anderlini, P., Donato, M., Cleary, K., Gajewski, J., Neumann, J., Ippoliti, C., Rondon, G., Cohen, A. & Champlin, R. (2004) Acute and chronic graft versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biology of Blood and Marrow Transplantation, 10, 178-185.
8. Dahl, D., Hahn, A., Koenecke, C., Heuft, H.-G., Dammann, E., Stadler, M., Buchholz, S., Krauter, J., Eder, M., Sykora, K.-W., Klein, C., Ganser, A. & Sauer, M. (2010) Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: Identification of patients at risk. Transfusion, 50, 549-655.
9. Damodar, S., George, B., Mammen, J., Mathews, V., Srivastava, A. & Chandy, M. (2005) Pre-transplant reduction of isohemagglutinins titers by donor type plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants. Bone Marrow Transplantation, 36, 233-235.
10. Fang, B., Song, Y., Li, N., Li, J., Han, Q. & Zhaol, R.C. (2009) Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Annals of Hematology, 88, 261-266.
11. Giralt, S. (2005) Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?. Hematology, 1, 384-389.
12. Giralt, S., Ballen, K., Rizzo, D., Bacigalupo, A., Horowitz, M., Pasquini, M. & Sandmaier, B. (2009) Reduced-intensity conditioning regimen workshop: Defining the dose spectrum Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biology of Blood Marrow Transplantation, 1, 367-369.
13. Griffiths, L.M., McCoy Jr J.P., Bolan, C.D., Stroneck, D.F., Pickett, A.C., Linton, G.F., Lundqvust, A., Srinivasan, R., Leitman, S.F. & Childs, R.W. (2005) Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. British Journal of Haematology, 128, 668-675.
14. Helbig, G., Steall-Holowiecka, B., Krawczk-Kulis, M., Wojnar, J., Markiewicz, M., Wojciechowska-Sadus, M., Kruzel, T., Najda, J., Nowak, K. & Holoweiecki, J. (2005) Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in 2 patients after ABO-incompatible allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Haematologica, 90, e93-96.
15. Helbig, G., Steall-Holowiecka, B., Wojnar, J., Krawczk, M., Krzemien, S., Wojciechowska-Sadus, M., Markiewicz, M., Wylezol, I., Kopera, M. & Holoweiecki, J. (2007) Pure Red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Annals of Hematology, 86, 677-683.
16. Lim, Z.Y., Fiaccadori, V., Gandhi, S., Hayden, J., Kenyon, M., Ireland, R., Marsh, J., Ho, A.Y., Mufti, G.J. & Pagliuca, A. (2010) Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving reduce intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia Research, 34, 723-727.
17. Majhail, N.S., Lazarus, H.M. & Burns, L.J. (2008) Iron overload in hematopoietic cell transplantation. Bone Marrow Transplantation, 41, 997-1003.
18. Musso, M., Porretto, F., Crescimanno, A., Polizzi, V. & Scalone, R. (2004) Case report. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation. Bone Marrow Transplantation, 33, 769-771.
19. Ozkurt, Z.N., Yegin, Z.A., Yenicesu, I., Aki, S.A., Yagci, M. & Sucak, G.T. (2009) Impact of ABO-incompatible donor in early and late outcome of hematopoietic stem cell transplantation. Transplantation Proceedings, 41, 3851-3858.
20. Poon, L.-M. & Koh, L.P. (2012) Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO mismatched allogeneic hematopoietic cell transplant using bortezomid. Bone Marrow Transplantation, 47, 870-871.
21. ® immunoadsorption. Bone Marrow Transplantation, 32, 1015-1019.
22. Sucak, G.T., Yegin, Z.A., Ozkurt, Z.N., Aki, S.K., Karakan, T. & Akyol, G. (2008) The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated. Bone Marrow Transplantation, 42, 461-467.
23. Worel, N., Kalhs, P., Keil, F., Prinz, E., Moser, K., Achulenburg, A., Mitterbauer, M., Mannhalter, C., Wolfgang, M.R., Schwarzinger, I., Hocker, P., Lechner, K. & Greinix, H.T. (2003) ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion, 43, 1153-1161.
24. Zhu, K.-E., Li, J.-P., Zhang, T., Zhong, J. & Chen, J. (2007) Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology, 12, 117-121.